Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesNeuroscientific Biopharmaceuticals Ltd

Neuroscientific Biopharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.041 AUD -0.01 ( 24.07%)
Last update at 2026-11-10T23:00:00Z
VOLUME
183032
Market Cap
21.04M

Momentum Score

…

Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Nedlands, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.04
Low
0.18
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Neuroscientific Biopharmaceuticals Ltd is an Australian biotechnology company listed on the ASX that appears positioned in the neuroscience therapeutics sector, though public disclosures about its programs are limited. Long-term growth drivers may include clinical development progress, successful regulatory outcomes and commercial partnerships or licensing that could advance its pipeline and address unmet needs in neurological disorders, which may benefit investors seeking exposure to neuroscience drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.40M
Revenue Per Share
0.00
Gross Profit TTM
0.26M
Debt / Equity
0.01
ROE
-29.68%
Net Debt
-2.54M
ROCE
-34.40%
Diluted EPS TTM
-0.01

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -5.10M -1.85M -1.89M -1.07M -10.44M
Net income -4.69M -1.85M 0.32M -1.07M -10.50M
Selling general administrative - 0.63M 0.65M 1.77M 2.73M
Selling and marketing expenses - 0.08M 0.08M - -
Gross profit -1.38M -0.09M -0.09M - -
Reconciled depreciation - 0.09M 0.09M 0.06M 0.06M
Ebit -5.11M -2.01M -1.89M -1.06M -10.50M
Ebitda -3.72M -1.92M -1.80M -1.01M -10.44M
Depreciation and amortization 1.38M 0.09M 0.09M 0.06M 0.06M
Operating income -5.11M -1.92M -2.06M -1.06M -10.50M
Other operating expenses 5.11M 1.92M 2.06M 6.12M 10.50M
Interest expense 0.00M 0.00M 0.01M 0.00M 0.07M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.17M 0.18M 0.00M 0.07M
Net interest income - 0.16M 0.17M 0.10M 0.07M
Income tax expense -0.40M - -2.21M 4.96M 0.07M
Total revenue - 0.17M 2.21M 5.06M 0.07M
Total operating expenses 3.72M 1.92M 1.97M 6.12M 10.50M
Cost of revenue 1.38M 0.00M 0.09M - -
Total other income expense net 0.01M 0.16M 0.17M 4.95M 0.07M
Net income from continuing ops - -1.85M 0.32M -1.07M -10.44M
Net income applicable to common shares - -1.85M 0.32M -1.07M -10.44M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 15.18M 16.96M 5.44M 5.29M 7.74M
Intangible assets 10.27M 9.57M - 0.27M 0.32M
Other current assets 0.04M - 0.04M 0.05M 0.06M
Total liab 0.37M 0.15M 0.09M 0.60M 2.22M
Total stockholder equity 14.81M 16.81M 5.35M 4.69M 5.52M
Other current liab 0.02M - 0.00M 0.01M 0.05M
Common stock 38.81M - 25.52M 25.27M 25.27M
Capital stock - 34.26M - 25.27M 25.27M
Retained earnings -26.71M -23.28M -22.04M -22.99M -22.60M
Cash 2.63M 7.27M 4.95M 4.91M 7.22M
Cash and equivalents - - - - 7.22M
Total current liabilities 0.34M 0.15M 0.09M 0.60M 2.22M
Net debt -2.54M - -4.95M -4.91M -7.22M
Short term debt 0.05M - - - 0.00M
Short long term debt total 0.09M - - - -
Other stockholder equity - - - 2.41M 2.84M
Property plant equipment - - - 0.01M 0.02M
Total current assets 4.80M 7.40M 5.04M 5.01M 7.40M
Net tangible assets - - - 4.42M 5.20M
Short term investments 2.00M - - - -
Net receivables 0.13M 0.07M 0.05M 0.04M 0.12M
Accounts payable 0.27M 0.15M 0.08M 0.59M 2.17M
Accumulated other comprehensive income 2.71M - 1.87M 2.41M 2.84M
Non currrent assets other - - 0.39M -0.28M -0.34M
Non current assets total 10.39M 9.57M 0.39M 0.28M 0.34M
Long term debt total - - - - 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.04M -0.00M - -0.00M
Change to liabilities - - - -1.58M 1.99M
Total cashflows from investing activities -2.00M -0.04M -0.00M 0.00M -0.00M
Total cash from financing activities -0.03M 3.29M 0.00M 0.00M 0.00M
Change to operating activities - - - -0.03M 0.16M
Net income -4.69M -1.85M 0.32M -1.07M -10.44M
Change in cash -4.64M 2.31M 0.04M -2.30M -6.95M
Begin period cash flow 7.27M 4.95M 4.91M 7.22M 14.16M
End period cash flow 2.63M 7.27M 4.95M 4.91M 7.22M
Total cash from operating activities -2.61M -0.94M 0.04M -2.30M -6.94M
Issuance of capital stock - 3.50M - - -
Depreciation 1.38M 0.09M 0.09M 0.06M 0.06M
Change to inventory - - - 1.61M -2.15M
Change to account receivables -0.03M -0.04M -0.01M 0.08M -0.07M
Sale purchase of stock - -0.21M - 0.00M 0.00M
Other cashflows from financing activities -0.02M - -0.00M - -0.00M
Change to netincome - - - 0.24M 1.35M
Capital expenditures 2.61M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.07M -0.04M -0.50M -1.54M 2.08M
Stock based compensation - 0.80M - 0.24M 1.35M
Other non cash items 0.63M 0.05M 0.55M 1.86M -0.44M
Free cash flow - -0.94M 0.04M -2.30M -6.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NSB
Neuroscientific Biopharmaceuticals Ltd		 -0.01
24.07%		 0.04 - - 52.26 1.18 39.23
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 -9.86

Profile*

Neuroscientific Biopharmaceuticals Ltd

Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Nedlands, Australia.

Level 1, Nedlands, WA, Australia, 6009

61 8 6268 2641

https://www.neuroscientific.com

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Interim CEO & CHairman 1959
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Sec. NA
Dougal Thring Chief Operating Officer NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…